Boston joins resorbable stent market with Synergy CE mark
This article was originally published in Clinica
Boston Scientific has joined Abbott in the resorbable stent market after getting the CE mark go-ahead for its fourth-generation SYNERGY drug-eluting stent (DES).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.